Lockheed Martin Investment Management Company Has Lowered By $1.29 Million Its Alexion Pharmaceuticals (ALXN) Stake; BW LPG LTD. ORDINARY SHARES BERMUDA (BWLLF) SI Increased By 13.94%

February 21, 2018 - By Adrian Mccoy

Lockheed Martin Investment Management Company decreased Alexion Pharmaceuticals Inc. (ALXN) stake by 53.49% reported in 2017Q3 SEC filing. Lockheed Martin Investment Management Company sold 9,200 shares as Alexion Pharmaceuticals Inc. (ALXN)’s stock declined 11.63%. The Lockheed Martin Investment Management Company holds 8,000 shares with $1.12 million value, down from 17,200 last quarter. Alexion Pharmaceuticals Inc. now has $26.11 billion valuation. The stock decreased 0.90% or $1.075 during the last trading session, reaching $117.775. About 371,327 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since February 21, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

BW LPG LTD. ORDINARY SHARES BERMUDA (OTCMKTS:BWLLF) had an increase of 13.94% in short interest. BWLLF’s SI was 1.22M shares in February as released by FINRA. Its up 13.94% from 1.07M shares previously. The SI to BW LPG LTD. ORDINARY SHARES BERMUDA’s float is 1.61%. It closed at $4.52 lastly. It is down 0.00% since February 21, 2017 and is . It has underperformed by 16.70% the S&P500.




BW LPG Limited, an investment holding company, engages in ship owning and chartering activities worldwide. The company has market cap of $591.68 million. The firm conducts its activities through Very Large Gas Carriers and Large Gas Carriers (LGCs) divisions. It has a 11.36 P/E ratio. It is involved in the transportation of liquefied petroleum gas (LPG) to oil companies, and trading and utility companies.

Since August 28, 2017, it had 0 buys, and 14 sales for $6.68 million activity. 120 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares with value of $16,800 were sold by Wagner Heidi L. 835 shares were sold by Veneman Ann M, worth $121,751 on Tuesday, September 5. HANTSON LUDWIG had sold 2,553 shares worth $310,521. On Thursday, August 31 O’Neill Julie sold $636,285 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 4,375 shares. 1,459 shares valued at $169,696 were sold by Franchini Indrani Lall on Tuesday, February 6. Moriarty John B had sold 3,363 shares worth $389,099. Shares for $192,028 were sold by Goff Brian.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.20, from 1.37 in 2017Q2. It is negative, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. Verity Asset accumulated 0.2% or 2,172 shares. Paradigm Asset Lc holds 0.02% or 500 shares. Tourbillon Cap Limited Partnership holds 1.58M shares. National Pension holds 0.16% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 204,795 shares. 11,000 were accumulated by Numeric Limited Liability Com. Sei Invs, a Pennsylvania-based fund reported 94,991 shares. The New York-based Goldman Sachs Gp has invested 0.12% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Cornerstone Cap Management Lc invested in 48,361 shares or 0.05% of the stock. Point72 Asset Management LP stated it has 0.04% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). State Board Of Administration Of Florida Retirement Sys holds 326,060 shares or 0.12% of its portfolio. Congress Asset Mgmt Com Ma holds 0.08% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 39,028 shares. 369 are held by Thompson Davis & Incorporated. Moreover, Art Advsr Limited Liability has 0.67% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 94,100 shares. Bluemountain Capital Limited holds 45,324 shares. Massachusetts-based De Burlo Gp has invested 0.64% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Lockheed Martin Investment Management Company increased Renaissancere Hldgs Ltd (NYSE:RNR) stake by 6,700 shares to 17,700 valued at $2.39 million in 2017Q3. It also upped Spdr S&P Oil & Gas Exploration (XOP) stake by 21,000 shares and now owns 315,000 shares. Select Sector Spdr (XLE) was raised too.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 100 analyst reports since July 27, 2015 according to SRatingsIntel. The company was maintained on Tuesday, October 24 by Leerink Swann. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Leerink Swann on Monday, September 25. Leerink Swann maintained it with “Buy” rating and $169.0 target in Wednesday, December 6 report. Deutsche Bank initiated the stock with “Buy” rating in Thursday, November 3 report. Oppenheimer initiated the stock with “Perform” rating in Thursday, December 15 report. On Thursday, February 25 the stock rating was initiated by Citigroup with “Neutral”. Citigroup maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, February 9 with “Buy” rating. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Leerink Swann on Wednesday, September 13. Morgan Stanley maintained the shares of ALXN in report on Friday, July 28 with “Buy” rating. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Tuesday, December 13.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on April, 26. They expect $1.28 EPS, up 6.67% or $0.08 from last year’s $1.2 per share. ALXN’s profit will be $283.75M for 23.00 P/E if the $1.28 EPS becomes a reality. After $1.28 actual EPS reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: